Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beamtree Holdings Limited (BMT.AX)
North Sydney, NSW, AU
Headquartered in Redfern, Australia, Beamtree Holdings Limited, founded in 1996, develops and markets cutting-edge clinical decision support (CDS) solutions for the healthcare sector, both within Australia and globally. The company offers a diverse range of products aimed at improving operational accuracy and patient outcomes. Among these are RippleDown Expert, providing live patient monitoring and notification capabilities, and RippleDown Auditor, which automates real-time data verification to ensure precision in billing, data entry, and specimen reception while identifying potential errors. Beamtree also offers PICQ, a quality assessment tool for clinically coded data used by public and private hospitals, health services, and state health authorities, alongside RISQ, designed for the measurement, benchmarking, and management of hospital-acquired complications. Further expanding its suite, the Q Coding Platform delivers an end-to-end workflow for clinical coding, grouping, reporting, and auditing, supported by Codexpert, a digital reference application for classification information in patient records. Additionally, the company provides expert advisory and auditing services, such as desktop analysis, data maturity assessments, and physical audits, reaching its clientele through strategic channel partners. The company adopted its current name, Beamtree Holdings Limited, in August 2021, having previously been known as PKS Holdings Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.13% | +20.00% | -20.00% | -40.00% | -56.36% | -57.33% | -66.32% | -63.08% | -77.14% | -46.67% | -46.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+3.6% Q4'25: +12.2% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%-17.7% Q4'25: +5.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-7.0% Q4'25: +2.2% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-22.1% Q4'25: -22.5% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%-15.7% Q4'25: -28.1% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+3.0% Q4'25: +5.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-4.04× Q4'25: -1.95× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.12M
est: 4.12M (+0.0%)
|
8.39M
est: 9.60M (-12.6%)
|
16.55M
est: 16.55M (0.0%)
|
22.77M
est: 23.52M (-3.2%)
|
27.60M
est: 27.60M (+0.0%)
|
28.60M
est: 29.00M (-1.4%)
|
29.88M
29.88M – 29.88M
+3.0% YoY
|
34.83M
34.83M – 34.83M
+16.6% YoY
|
39.66M
39.66M – 39.66M
+13.9% YoY
|
44.71M
44.71M – 44.71M
+12.7% YoY
|
| EBITDA |
697.1K
est: -92.5K (+853.5%)
|
1.02M
est: -215.3K (+573.4%)
|
-2.28M
est: -371.2K (-515.3%)
|
-1.26M
est: -527.6K (-139.2%)
|
-331.0K
est: -619.1K (+46.5%)
|
-808.0K
est: -650.5K (-24.2%)
|
-670.3K
-670.3K – -670.3K
-3.0% YoY
|
-781.3K
-781.3K – -781.3K
-16.6% YoY
|
-889.6K
-889.6K – -889.6K
-13.9% YoY
|
-1.00M
-1.00M – -1.00M
-12.7% YoY
|
| EBIT |
189.4K
est: -919.1K (+120.6%)
|
-477.5K
est: -2.14M (+77.7%)
|
-5.90M
est: -3.69M (-60.0%)
|
-6.16M
est: -5.24M (-17.4%)
|
-5.77M
est: -6.15M (+6.1%)
|
-6.32M
est: -6.46M (+2.1%)
|
-6.66M
-6.66M – -6.66M
-3.1% YoY
|
-7.76M
-7.76M – -7.76M
-16.6% YoY
|
-8.84M
-8.84M – -8.84M
-13.9% YoY
|
-9.96M
-9.96M – -9.96M
-12.7% YoY
|
| Net Income |
382.9K
est: 753.1K (-49.2%)
|
-383.6K
est: 4.05M (-109.5%)
|
-4.45M
est: -2.90M (-53.6%)
|
-6.91M
est: -6.65M (-4.0%)
|
-5.11M
est: -3.88M (-31.6%)
|
-6.16M
est: -5.79M (-6.3%)
|
-4.26M
-4.26M – -4.26M
+26.4% YoY
|
-1.97M
-1.97M – -1.97M
+53.7% YoY
|
489.5K
489.5K – 489.5K
+124.8% YoY
|
2.17M
2.17M – 2.17M
+344.2% YoY
|
| SGA |
1.88M
est: 1.14M (+65.7%)
|
1.91M
est: 2.65M (-27.8%)
|
1.27M
est: 4.56M (-72.2%)
|
2.55M
est: 6.49M (-60.7%)
|
3.19M
est: 7.61M (-58.0%)
|
24.21M
est: 8.00M (+202.7%)
|
8.24M
8.24M – 8.24M
+3.0% YoY
|
9.60M
9.60M – 9.60M
+16.6% YoY
|
10.94M
10.94M – 10.94M
+13.9% YoY
|
12.33M
12.33M – 12.33M
+12.7% YoY
|
| EPS |
0.00
est: 0.00 (+19.2%)
|
0.00
est: 0.01 (-113.6%)
|
-0.02
est: -0.01 (-85.0%)
|
-0.03
est: -0.02 (-22.0%)
|
-0.02
est: -0.01 (-35.1%)
|
-0.02
est: -0.02 (-6.5%)
|
-0.01
-0.01 – -0.01
+26.4% YoY
|
-0.01
-0.01 – -0.01
+53.7% YoY
|
0.00
0.00 – 0.00
+124.8% YoY
|
0.01
0.01 – 0.01
+344.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marek Stepniak | Chief Executive Officer | 537.4K | male |
| Cheryl McCullagh | Chief Clinical & Innovation Officer | 445.4K | female |
| Emma Gray | Executive Chairman | 80.0K | female |
| Kateena Mills | Head of People & Culture | — | female |
| Larissa Mason | Head of Clinical Decision Support | — | female |
| Michael Reakes | General Manager | — | male |
| Michelle Spiller | Chief Financial Officer | — | female |
| Stephen Badham | Head of Coding & Data Quality | — | male |
| Evan Simmons | Head of Diagnostics | — | male |
| Stephen Morgan | Chief Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BMT.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
